Altace

As far as Altace goes, we commented on the last call and we're very happy with the fact we've been able to hang on to as of the end of the third quarter a little over 8\% of total prescriptions for branded Altace which is highly unusual particularly with an ACE inhibitor once you have multiple generic competitors in the marketplace.

SeekingAlpha.com: Home Page 2008

King is still struggling to find a replacement for its once-best-selling Altace blood-pressure treatment, whose sales have plunged due to generic competition.

King Pharmaceuticals Profit Falls 53% 2010

Since it lost a 2007 patent case involving its once top-selling Altace blood-pressure drug, King had shifted its focus onto other products, including Skelaxin.

King Pharmaceuticals Cuts 22% of Work Force 2009

In the first quarter, branded-pharmaceutical sales dropped 25% on the Altace woes.

King Pharmaceuticals Swings to Loss on Acquisition Charges 2009

Since it lost a 2007 patent case involving Altace, King had shifted its focus onto other products, including Skelaxin.

King Pharmaceuticals Swings to Loss on Acquisition Charges 2009

King Pharmaceuticals Inc. swung to a first-quarter loss on acquisition-related costs as branded-drug sales skidded, with its once top-seller Altace blood-pressure drug tumbling amid generic competition.

King Pharmaceuticals Swings to Loss on Acquisition Charges 2009

By contrast, Altace sales, under pressure since a generic rival was introduced in December, 2007, plunged 82%.

King Pharmaceuticals Cuts 22% of Work Force 2009

Revenue dipped 0.7% to $429.1 million amid the acquisition while Altace sales tumbled 88%.

King Pharmaceuticals Swings to Loss on Acquisition Charges 2009

Earlier this month, King reported that its second-quarter net income tumbled 34% as sales of its former top-seller Altace blood-pressure drug were hampered by an influx of generic brands.

Alpharma Rejects Bid From King 2008

I have high blood pressure, but I am taking Altace to control it.

CNN Transcript Mar 14, 2007 2007